ZyVersa Therapeutics

Company snapshot

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kid

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ZyVersa Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ZyVersa Therapeutics.

1. May 23, 2026 Clinical update

   2HPβCD — Phase 2

View all clinical trial activity →

• What is ZyVersa Therapeutics?

  ZyVersa Therapeutics is a pharma organization headquartered in Weston, USA. It trades on NYSE under ticker ZVSA. Primary therapeutic focus areas include Diabetic Kidney Disease. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity f

• Is ZyVersa Therapeutics publicly traded?

  Yes. ZyVersa Therapeutics is listed with ticker ZVSA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ZyVersa Therapeutics develop or market?

  No drug profiles are currently linked to ZyVersa Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for ZyVersa Therapeutics?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ZyVersa Therapeutics focus on?

  ZyVersa Therapeutics focuses on Diabetic Kidney Disease based on our analysis of their pipeline programs and drug development activities.